The pre-market session saw significant movements in various stocks, driven by factors such as strong guidance, mergers and acquisitions, and regulatory developments. ImmunityBio, a biotech company, jumped 13% after providing strong guidance for its bladder cancer drug Anktiva, which is expected to drive a 700% increase in full-year revenue. This surge added to the company’s 30% rally in the previous session, demonstrating the market’s confidence in the drug’s potential.<\/p>\n
Worthington Steel, a Columbus, Ohio-based steel manufacturer, climbed 7% after agreeing to acquire Germany’s Kloeckner & Co., a metal processor, for an enterprise value of $2.4 billion. This strategic move is expected to expand Worthington Steel’s capabilities and market reach. In contrast, QXO, a roofing products maker, saw its shares fall 7% after announcing plans to sell $750 million in common stock, which may have raised concerns among investors about potential dilution.<\/p>\n
PNC, a Pittsburgh-based bank, rose 4% after posting better-than-expected fourth-quarter results, with revenue of $5.96 billion exceeding the consensus estimate of $5.89 billion. The bank’s earnings of $4.88 per share also surpassed the forecast of $4.22 per share, demonstrating its strong financial performance. Additionally, PNC projected total revenue growth of roughly 11% by the end of 2026, outpacing the 8.7% estimated by analysts. Honeywell, an industrial giant, ticked nearly 2% higher after receiving an upgrade to overweight from neutral at JPMorgan, citing the company’s planned break-up as a positive factor.<\/p>\n
Energy stocks, including GE Vernova and Bloom Energy, gained 3%, while Oklo ticked up more than 1%, following the Trump administration’s push for an emergency auction to encourage technology companies to invest in power plants. This move is aimed at addressing the rising energy demands of data centers, which are becoming increasingly significant consumers of energy.<\/p>\n